JP5456235B2 - 神経変性疾患を治療するためのワクチン及び方法 - Google Patents

神経変性疾患を治療するためのワクチン及び方法 Download PDF

Info

Publication number
JP5456235B2
JP5456235B2 JP2006539072A JP2006539072A JP5456235B2 JP 5456235 B2 JP5456235 B2 JP 5456235B2 JP 2006539072 A JP2006539072 A JP 2006539072A JP 2006539072 A JP2006539072 A JP 2006539072A JP 5456235 B2 JP5456235 B2 JP 5456235B2
Authority
JP
Japan
Prior art keywords
mice
disease
cells
cop1
aggregated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2006539072A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007513079A (ja
JP2007513079A5 (cg-RX-API-DMAC7.html
Inventor
− シュワルツ、ミハエル アイゼンバッハ
ヨーレス、エスター
ブトフスキー、オレグ
キプニス、ジョナサン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Publication of JP2007513079A publication Critical patent/JP2007513079A/ja
Publication of JP2007513079A5 publication Critical patent/JP2007513079A5/ja
Application granted granted Critical
Publication of JP5456235B2 publication Critical patent/JP5456235B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2006539072A 2003-11-12 2004-11-11 神経変性疾患を治療するためのワクチン及び方法 Expired - Fee Related JP5456235B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US51862703P 2003-11-12 2003-11-12
US60/518,627 2003-11-12
US61096604P 2004-09-20 2004-09-20
US60/610,966 2004-09-20
PCT/IL2004/001037 WO2005046719A1 (en) 2003-11-12 2004-11-11 Vaccine and method for treatment of neurodegenerative diseases

Publications (3)

Publication Number Publication Date
JP2007513079A JP2007513079A (ja) 2007-05-24
JP2007513079A5 JP2007513079A5 (cg-RX-API-DMAC7.html) 2008-01-10
JP5456235B2 true JP5456235B2 (ja) 2014-03-26

Family

ID=34594916

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006539072A Expired - Fee Related JP5456235B2 (ja) 2003-11-12 2004-11-11 神経変性疾患を治療するためのワクチン及び方法

Country Status (7)

Country Link
US (3) US20080085269A1 (cg-RX-API-DMAC7.html)
EP (2) EP1684797A1 (cg-RX-API-DMAC7.html)
JP (1) JP5456235B2 (cg-RX-API-DMAC7.html)
AU (1) AU2004288654B2 (cg-RX-API-DMAC7.html)
CA (1) CA2546077C (cg-RX-API-DMAC7.html)
IL (2) IL175535A (cg-RX-API-DMAC7.html)
WO (1) WO2005046719A1 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2527760T3 (es) * 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
CA2546077C (en) 2003-11-12 2016-07-05 Yeda Research And Development Co. Ltd. Vaccine and method for treatment of neurodegenerative diseases
DK1701730T3 (da) * 2003-12-09 2013-11-25 Yeda Res & Dev Fremgangsmåde og vaccine omfattende copolymer 1 til behandling af psykiatriske forstyrrelser
WO2009040814A1 (en) 2007-09-24 2009-04-02 Hadasit Medical Research Services & Development Ltd Use of copolymer 1 for treatment of muscular dystrophy
WO2010019270A1 (en) * 2008-08-14 2010-02-18 Isis Pharmaceuticals, Inc. Modulation of prion expression
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8759302B2 (en) * 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
EA025780B1 (ru) 2010-10-11 2017-01-30 Тева Фармасьютикал Индастриз Лтд. Цитокиновые биомаркеры в качестве биомаркеров, прогнозирующих клинический ответ на глатирамер ацетат
ES2601892T3 (es) 2011-04-21 2017-02-16 Mapi Pharma Limited Pentapolímero aleatorio para el tratamiento de enfermedades autoinmunes
MX2014004309A (es) 2011-10-10 2015-07-06 Teva Pharma Polimorfismos de nucleotidos individuales utiles para predecir una respuesta clinica para el acetato de glatiramer.
WO2013059322A2 (en) * 2011-10-17 2013-04-25 Lawrence Steinman Amyloid beta peptide as a therapy for inflammation
EP3027205A4 (en) 2013-07-28 2017-07-19 Qantu Therapeutics, Inc. Vaccine formulations that induce a th2 immune response
US10519237B2 (en) 2014-03-12 2019-12-31 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US10618963B2 (en) 2014-03-12 2020-04-14 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
KR20200029627A (ko) * 2014-03-12 2020-03-18 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 Cns의 질환 및 손상을 치료하기 위한 전신적 조절 t 세포 수준 또는 활성의 감소
US11058720B2 (en) * 2016-05-20 2021-07-13 Cedars-Sinai Medical Center Methods of treating or preventing alzheimer's disease and associated conditions
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
AU2017319728B2 (en) 2016-08-31 2024-09-05 Mapi Pharma Ltd Depot systems comprising glatiramer acetate
IL316573A (en) 2017-03-26 2024-12-01 Mapi Pharma Ltd Storage systems containing glatiramer acetate for the treatment of multiple sclerosis
US12281305B2 (en) 2018-11-21 2025-04-22 Ionis Pharmaceuticals, Inc. Compounds and methods for reducing prion expression
EP3725370A1 (en) 2019-04-19 2020-10-21 ImmunoBrain Checkpoint, Inc. Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL36670A (en) 1971-04-21 1974-09-10 Sela M Therapeutic basic copolymers of amino acids
US6071970A (en) * 1993-02-08 2000-06-06 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
IL113812A (en) 1994-05-24 2000-06-29 Yeda Res & Dev Copolymer-1 pharmaceutical compositions containing it and its use
US6717031B2 (en) 1995-06-07 2004-04-06 Kate Dora Games Method for selecting a transgenic mouse model of alzheimer's disease
US6794414B1 (en) * 1998-06-17 2004-09-21 Yeda Research And Development Co. Ltd. Method and compositions for treating diseases mediated by transglutaminase activity
EP1098902A4 (en) 1998-07-23 2002-07-24 Yeda Res & Dev TREATMENT OF AUTOIMMUNE DISEASES WITH COPOLYMER 1 AND RELATED COPOLYMERS AND PEPTIDES
JP2003521448A (ja) 1998-07-23 2003-07-15 ザ・プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ 合成ペプチドおよび自己免疫疾患治療のための使用方法
HK1054507B (zh) * 2000-01-20 2008-10-31 耶达研究及发展有限公司 共聚物1和相关肽和多肽及其处理过的t细胞在神经保护性治疗中的用途
DE60116467T2 (de) * 2000-06-07 2006-11-02 Yeda Research And Development Co., Ltd. Verwendung des Copolymer-1 Peptids sowie von damit verwandten Peptiden und Polypeptiden und von damit behandelten T-Zellen zur Neuroprotektion gegen die Toxizität von Glutamat
IL148202A0 (en) * 2000-06-20 2002-09-12 Caprion Pharmaceuticals Inc Copolymers and methods of treating prion-related diseases
ES2387082T3 (es) * 2001-05-17 2012-09-13 Merck Serono Sa Uso de OSTEOPONTINA para el tratamiento y/o prevención de enfermedades neurológicas
US7718699B1 (en) * 2005-03-04 2010-05-18 Broyles Robert H Abscissic acid and derivatives thereof for the treatment of diseases
US7351686B2 (en) 2001-12-06 2008-04-01 Yeda Research And Development Co. Ltd. Method for neuronal protection in amyotrophic lateral sclerosis by a vaccine comprising Copolymer-1 or Copolymer-1 related peptides
CA2546077C (en) 2003-11-12 2016-07-05 Yeda Research And Development Co. Ltd. Vaccine and method for treatment of neurodegenerative diseases
US7220729B2 (en) * 2004-05-10 2007-05-22 Academia Sinica Huntington's Disease Treatment

Also Published As

Publication number Publication date
US20110206706A1 (en) 2011-08-25
US20080085269A1 (en) 2008-04-10
JP2007513079A (ja) 2007-05-24
US20140134196A1 (en) 2014-05-15
CA2546077C (en) 2016-07-05
IL224393B (en) 2018-06-28
CA2546077A1 (en) 2005-05-26
AU2004288654B2 (en) 2009-12-03
US8828404B2 (en) 2014-09-09
IL175535A0 (en) 2006-09-05
EP1684797A1 (en) 2006-08-02
WO2005046719A1 (en) 2005-05-26
EP2301569A2 (en) 2011-03-30
US9517256B2 (en) 2016-12-13
IL175535A (en) 2016-03-31
EP2301569B1 (en) 2018-05-02
AU2004288654A1 (en) 2005-05-26
EP2301569A3 (en) 2011-07-06

Similar Documents

Publication Publication Date Title
US9517256B2 (en) Vaccine and method for treatment of neurodegenerative diseases
US9089509B2 (en) Method of treatment of age-related macular degeneration
CA2451521C (en) Use of poly-glu, tyr for neuroprotective therapy
CA2469092C (en) Copolymer 1 vaccine and methods for treatment of amyotrophic lateral sclerosis (als)
EP4034550A1 (en) Vaccine therapy for ran protein diseases
US7399740B2 (en) Poly-Glu,Tyr for neuroprotective therapy
US20050220803A1 (en) Use of an organ-specific self-pathogen for treatment of a non-autoimmune disease of said organ
US20110117115A1 (en) Method and vaccine comprising copolymer 1 for treatment of psychiatric disorders
JP4808631B2 (ja) 精神医学的障害の治療用のコポリマー1を含む方法及びワクチン
US20110033488A1 (en) Agents and methods for treatment of anxiety disorders
US9610326B2 (en) Amyloid beta peptides as therapy for multiple sclerosis
HK1127858B (en) Copolymer-1 for treatment of age-related macular degeneration
IL176217A (en) Pharmaceutical compositions comprising copolymer 1 for treatment of post-traumatic stress disorder (ptsd), schizophrenia, depression or bipolar disorder
HK1064951B (en) Use of poly-glu, tyr for neuroprotection therapy of the cns or pns

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071112

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071112

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101005

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101228

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110124

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110620

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20110621

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20110810

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20110913

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130312

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131119

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140108

R150 Certificate of patent or registration of utility model

Ref document number: 5456235

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees